REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Reviva Pharmaceuticals Holdings, Inc.
- 3.1%
- 403.3K
- 6.73
Float 12.86M · Signal8 dilution snapshot · Nov 13, 2026
The cost to borrow RVPH shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 2.5%
- 293
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 403.3K sh |
| Oct 15, 2026 | 400.2K sh |
| Sep 30, 2026 | 402.0K sh |
| Sep 15, 2026 | 405.1K sh |
| Aug 31, 2026 | 400.3K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 29, 2026 | 293 sh |
| Oct 6, 2026 | 185 sh |
| Sep 17, 2026 | 2 sh |
| Sep 3, 2026 | 252 sh |
| Sep 2, 2026 | 368 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 2.5% |
| Nov 16, 2026 | 28.9% |
| Nov 13, 2026 | 45.4% |
| Nov 12, 2026 | 24.4% |
| Nov 11, 2026 | 30.7% |
130 calendar days requested; 84 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for RVPH: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 403,277 RVPH shares were sold short (3.14% of a 12.86M-share float, 6.73 days to cover).